Cencora, Inc. (NYSE:COR) Shares Bought by Strategic Blueprint LLC

Strategic Blueprint LLC raised its stake in Cencora, Inc. (NYSE:COR) by 31.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,244 shares of the company’s stock after acquiring an additional 301 shares during the period. Strategic Blueprint LLC’s holdings in Cencora were worth $280,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Rise Advisors LLC acquired a new position in Cencora in the 1st quarter valued at $25,000. New Millennium Group LLC purchased a new position in shares of Cencora during the 2nd quarter worth approximately $26,000. Legacy Bridge LLC acquired a new stake in shares of Cencora in the 1st quarter valued at approximately $27,000. TCTC Holdings LLC acquired a new position in Cencora during the first quarter worth $29,000. Finally, TFO Wealth Partners LLC purchased a new position in Cencora in the first quarter worth $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,452,273 shares of company stock worth $1,070,812,312. 15.80% of the stock is currently owned by insiders.

Cencora Price Performance

COR stock traded down $0.21 during trading on Thursday, hitting $236.24. The stock had a trading volume of 18,865 shares, compared to its average volume of 1,357,089. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $247.66. The stock has a market cap of $47.12 billion, a price-to-earnings ratio of 25.87, a price-to-earnings-growth ratio of 1.68 and a beta of 0.45. The company’s 50 day moving average price is $231.76 and its two-hundred day moving average price is $232.83. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.53 and a current ratio of 0.89.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.92 earnings per share. On average, sell-side analysts forecast that Cencora, Inc. will post 13.56 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Leerink Partners reiterated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a report on Thursday, June 27th. JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Wells Fargo & Company lifted their price objective on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, Robert W. Baird increased their price objective on shares of Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $258.63.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.